Radhakrishnan Maha

Radhakrishnan Maha is listed in filings as Director at Candel Therapeutics, Inc.. This profile follows SEC Form 4 activity through Jun 6, 2025, including 2 public disclosures. Recent filings connect the profile to Candel Therapeutics, Inc. (CADL) and Entrada Therapeutics, Inc. (TRDA). The current snapshot covers public activity from Jun 3, 2025 to Jun 6, 2025. Reported amounts are shown as $159.5K to $288.8K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.